HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reconstruction of Peri-implant Osseous Defects: A Multicenter Randomized Trial.

Abstract
There is a paucity of data for the effectiveness of reconstructive procedures in the treatment of peri-implantitis. The objective of this study was to compare reconstruction of peri-implant osseous defects with open flap debridement (OFD) plus porous titanium granules (PTGs) compared with OFD alone. Sixty-three patients (36 female, 27 male; mean age 58.4 y [SD 12.3]), contributing one circumferential peri-implant intraosseous defect, were included in a multinational, multicenter randomized trial using a parallel-group design. After OFD and surface decontamination using titanium brushes and hydrogen peroxide, 33 defects received PTGs. The implants were not submerged. All patients received adjunctive perioperative systemic antibiotics. The primary outcome variable (defect fill) was assessed on digitalized radiographs. Clinical measurements of probing depth (PPD), bleeding on probing (BoP), suppuration, and plaque were taken by blinded examiners. After 12 mo, the test group (OFD plus PTG) showed a mean radiographic defect fill (mesial/distal) of 3.6/3.6 mm compared with 1.1/1.0 in the control group (OFD). Differences were statistically significant in favor of the test group (P < 0.0001). The OFD plus PTG group showed a mean reduction in PPD of 2.8 mm compared with 2.6 mm in the OFD group. BoP was reduced from 89.4% to 33.3% and from 85.8% to 40.4% for the test and control groups, respectively. There was no significant difference in complete resolution of peri-implantitis (PPD ≤4 mm and no BoP at six implant sites and no further bone loss), because this finding was accomplished at 30% of implants in the test group and 23% of implants in the control group. Reconstructive surgery using PTGs resulted in significantly enhanced radiographic defect fill compared with OFD. However, limitations in the lack of ability to discern biomaterial from osseous tissue could not be verified to determine new bone formation. Similar improvements according to clinical measures were obtained after both surgical treatment modalities (ClinicalTrials.gov NCT02406001).
AuthorsK Jepsen, S Jepsen, M L Laine, D Anssari Moin, A Pilloni, B Zeza, M Sanz, A Ortiz-Vigon, A M Roos-Jansåker, S Renvert
JournalJournal of dental research (J Dent Res) Vol. 95 Issue 1 Pg. 58-66 (Jan 2016) ISSN: 1544-0591 [Electronic] United States
PMID26450511 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© International & American Associations for Dental Research 2015.
Chemical References
  • Anti-Bacterial Agents
  • Anti-Infective Agents, Local
  • Biocompatible Materials
  • Bone Substitutes
  • Dental Disinfectants
  • Metronidazole
  • Amoxicillin
  • Hydrogen Peroxide
  • Titanium
  • Chlorhexidine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amoxicillin (therapeutic use)
  • Anti-Bacterial Agents (therapeutic use)
  • Anti-Infective Agents, Local (therapeutic use)
  • Biocompatible Materials (chemistry)
  • Bone Substitutes (chemistry)
  • Chlorhexidine (therapeutic use)
  • Combined Modality Therapy
  • Debridement (methods)
  • Dental Disinfectants (therapeutic use)
  • Female
  • Follow-Up Studies
  • Gingival Hemorrhage (surgery)
  • Humans
  • Hydrogen Peroxide (therapeutic use)
  • Male
  • Metronidazole (therapeutic use)
  • Middle Aged
  • Peri-Implantitis (surgery)
  • Periodontal Pocket (surgery)
  • Prospective Studies
  • Plastic Surgery Procedures (methods)
  • Titanium (chemistry)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: